Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
17
01
2024
accepted:
02
09
2024
revised:
29
08
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
Patients suffering from strokes are at increased risk of developing post-stroke dementia. Serum anti-NMDA receptor autoantibodies (NMDAR1-abs) have been associated with unfavorable post-stroke outcomes. However, their effect on specific cognitive domains remains unclear. We used data from the prospective multicenter DZNE-mechanisms after stroke (DEMDAS) cohort, and measured NMDAR1-abs in serum at baseline. Cognitive function was assessed with a comprehensive neuropsychological test battery at 6- and 12-months follow-up. We employed crude and stepwise confounder adjusted linear and logistic regression models as well as generalized estimating equation models (GEE) to determine the relevance of NMDAR1-abs seropositivity on cognitive function after stroke. 10.2% (58/569) DEMDAS patients were NMDAR1-abs seropositive (IgM:n = 44/IgA:n = 21/IgG:n = 2). Seropositivity was not associated with global cognitive impairment after stroke. However, NMDAR1-abs seropositive patients performed lower in the memory domain (β
Identifiants
pubmed: 39478168
doi: 10.1038/s41380-024-02744-w
pii: 10.1038/s41380-024-02744-w
doi:
Banques de données
ClinicalTrials.gov
['NCT01334749']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsches Zentrum für Neurodegenerative Erkrankungen (German Center for Neurodegenerative Diseases)
ID : MC002
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC-2049 - 390688087
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 5023 BeCAUSE-Y, project 2 EN343/16-1
Investigateurs
Matthias Endres
(M)
Thomas Liman
(T)
Christian Nolte
(C)
Lucia Kerti
(L)
Tatjana Wittenberg
(T)
Jan F Scheitz
(JF)
Pia S Sperber
(PS)
Alexander H Nave
(AH)
Anna Ibaroule Kufner
(AI)
Felix Bode
(F)
Sebastian Stösser
(S)
Julius N Meißner
(JN)
Taraneh Ebrahimi
(T)
Julia Nordsiek
(J)
Niklas Beckonert
(N)
Peter Hermann
(P)
Matthias Schmitz
(M)
Stefan Goebel
(S)
Julia Schütte-Schmidt
(J)
Sabine Nuhn
(S)
Corinna Volpers
(C)
Peter Dechent
(P)
Matthias Bähr
(M)
Wenzel Glanz
(W)
Marios Georgakis
(M)
Steffen Tiedt
(S)
Karin Waegemann
(K)
Daniel Janowitz
(D)
Benno Ikenberg
(B)
Kathleen Bermkopf
(K)
Christiane Huber
(C)
Michael Wagner
(M)
Katja Neumann
(K)
Annika Spottke
(A)
Tony Stöcker
(T)
Marco Dühring
(M)
Oliver Speck
(O)
Emrah Duezel
(E)
Peter Bartenstein
(P)
Informations de copyright
© 2024. The Author(s).
Références
Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–58.
doi: 10.1016/S1474-4422(19)30034-1
Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006–18.
pubmed: 19782001
doi: 10.1016/S1474-4422(09)70236-4
Pendlebury ST, Rothwell PM, Oxford VS. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol. 2019;18:248–58.
pubmed: 30784556
pmcid: 6390174
doi: 10.1016/S1474-4422(18)30442-3
Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke. 2012;43:3137–46.
pubmed: 22935401
doi: 10.1161/STROKEAHA.112.651778
Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76:82–94.
Steiner J, Teegen B, Schiltz K, Bernstein HG, Stoecker W, Bogerts B. Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry. 2014;71:838–9.
pubmed: 24871043
doi: 10.1001/jamapsychiatry.2014.469
Sperber PS, Siegerink B, Huo S, Rohmann JL, Piper SK, Pruss H, et al. Serum anti-NMDA (N-methyl-D-aspartate)-receptor antibodies and long-term clinical outcome after stroke (PROSCIS-B). Stroke. 2019;50:3213–9.
pubmed: 31526121
doi: 10.1161/STROKEAHA.119.026100
Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, et al. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol. 2014;1:822–32.
pubmed: 25493273
pmcid: 4241809
doi: 10.1002/acn3.120
During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons H, et al. An oral vaccine against NMDARI with efficacy in experimental stroke and epilepsy. Science. 2000;287:1453–60.
Zerche M, Weissenborn K, Ott C, Dere E, Asif AR, Worthmann H, et al. Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke. Stroke. 2015;46:1180–6.
pubmed: 25765725
doi: 10.1161/STROKEAHA.114.008323
Sperber PS, Gebert P, Broersen LHA, Huo S, Piper SK, Teegen B, et al. Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). J Neurol. 2022;269:5521–30.
pubmed: 35718820
pmcid: 9468072
doi: 10.1007/s00415-022-11203-x
Deutsch NR, Worthmann H, Steixner-Kumar AA, Schuppner R, Grosse GM, Pan H, et al. Autoantibodies against the NMDAR subunit NR1 are associated with neuropsychiatric outcome after ischemic stroke. Brain Behav Immun. 2021;96:73–9.
pubmed: 34010714
doi: 10.1016/j.bbi.2021.05.011
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol. 2023;22:268–82.
pubmed: 36706773
doi: 10.1016/S1474-4422(22)00431-8
Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology. 2012;78:1743–53.
pubmed: 22539565
pmcid: 3359581
doi: 10.1212/WNL.0b013e318258300d
Bartels F, Stronisch T, Farmer K, Rentzsch K, Kiecker F, Finke C. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol. 2019;30:823–9.
pubmed: 30840061
pmcid: 6551450
doi: 10.1093/annonc/mdz083
Finke C, Bartels F, Lutt A, Pruss H, Harms L. High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients. J Neurol. 2017;264:1968–77.
pubmed: 28785798
doi: 10.1007/s00415-017-8582-0
Ehrenreich H, Wilke J, Steixner-Kumar AA. Spontaneous serum autoantibody fluctuations: To be or not to be. Mol Psychiatry. 2021;26:1723–5.
pubmed: 32968237
doi: 10.1038/s41380-020-00883-4
Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. 2014;19:1143–9.
pubmed: 23999527
doi: 10.1038/mp.2013.110
Wollenweber FA, Zietemann V, Rominger A, Opherk C, Bayer-Karpinska A, Gschwendtner A, et al. The determinants of dementia after stroke (DEDEMAS) study: protocol and pilot data. Int J Stroke. 2014;9:387–92.
pubmed: 23834337
doi: 10.1111/ijs.12092
Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24:145–53.
pubmed: 8208879
doi: 10.1017/S003329170002691X
Ramberger M, Peschl P, Schanda K, Irschick R, Hoftberger R, Deisenhammer F, et al. Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating N-methyl-D-aspartate receptor antibodies in serum using a live cell-based assay. PLoS One. 2015;10:e0122037.
pubmed: 25815887
pmcid: 4376531
doi: 10.1371/journal.pone.0122037
Berres M, Monsch AU, Bernasconi F, Thalmann B, Stähelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Inform. 2000;77:195–9.
Georgakis MK, Fang R, During M, Wollenweber FA, Bode FJ, Stosser S, et al. Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study. Alzheimers Dement. 2023;19:1152–63.
pubmed: 35876563
doi: 10.1002/alz.12744
Folstein MF, Folstein SE, Mchugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Somerville J, Tremont G, Stern RA. The Boston Qualitative Scoring System as a measure of executive functioning in Rey-Osterrieth Complex Figure performance. J Clin Exp Neuropsychol. 2000;22:613–21.
pubmed: 11094396
doi: 10.1076/1380-3395(200010)22:5;1-9;FT613
Bäumler G. Farb-Wort-Interferenztest (FWIT) nach J.R. Stroop. Germany: Hogrefe Göttingen; 1985.
Young JC, Sawyer RJ, Roper BL, Baughman BC. Expansion and re-examination of Digit Span effort indices on the WAIS-IV. Clin Neuropsychol. 2012;26:147–59.
pubmed: 22268525
doi: 10.1080/13854046.2011.647083
Knopman DS, Beiser A, Machulda MM, Fields J, Roberts RO, Pankratz VS, et al. Spectrum of cognition short of dementia Framingham heart study and Mayo Clinic study of aging. Neurology. 2015;85:1712–21.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
Zietemann V, Georgakis MK, Dondaine T, Muller C, Mendyk AM, Kopczak A, et al. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology. 2018;91:e1838–e50.
pubmed: 30333158
doi: 10.1212/WNL.0000000000006506
Burton L, Tyson SF. Screening for cognitive impairment after stroke: a systematic review of psychometric properties and clinical utility. J Rehabil Med. 2015;47:193–203.
pubmed: 25590458
doi: 10.2340/16501977-1930
Frick J, Gebert P, Grittner U, Letsch A, Schindel D, Schenk L. Identifying and handling unbalanced baseline characteristics in a non-randomized, controlled, multicenter social care nurse intervention study for patients in advanced stages of cancer. BMC Cancer. 2022;22:560.
pubmed: 35585571
pmcid: 9118792
doi: 10.1186/s12885-022-09646-6
Jahn R, Baumgartner JS, van den Nest M, Friedrich F, Alexandrowicz RW, Wancata J. [Criterion validity of the German version of the CES-D in the general population]. Psychiatr Prax. 2018;45:434–42.
pubmed: 29665610
Parikh RM, Eden DT, Price TR, Robinson RG. The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for post-stroke depression. Int J Psychiatry Med. 1988;18:169–81.
pubmed: 3170080
doi: 10.2190/BH75-EUYA-4FM1-J7QA
Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer. 1996;4:82–96.
pubmed: 8673356
doi: 10.1007/BF01845757
Mead G, Lynch J, Greig C, Young A, Lewis S, Sharpe M. Evaluation of fatigue scales in stroke patients. Stroke. 2007;38:2090–5.
pubmed: 17525397
doi: 10.1161/STROKEAHA.106.478941
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.
doi: 10.1016/S0140-6736(07)61602-X
Royl G, Fokou TJ, Chunder R, Isa R, Munte TF, Wandinger KP, et al. Antibodies against neural antigens in patients with acute stroke: joint results of three independent cohort studies. J Neurol. 2019;266:2772–9.
pubmed: 31359201
doi: 10.1007/s00415-019-09470-2
Daguano Gastaldi V, Bh Wilke J, Weidinger CA, Walter C, Barnkothe N, Teegen B, et al. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immun. 2023;108:135–47.
pubmed: 36323361
doi: 10.1016/j.bbi.2022.10.016
Pruss H, Iggena D, Baldinger T, Prinz V, Meisel A, Endres M, et al. Evidence of intrathecal immunoglobulin synthesis in stroke: a cohort study. Arch Neurol. 2012;69:714–7.
pubmed: 22371852
doi: 10.1001/archneurol.2011.3252
Ehrenreich H. Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease. Curr Opin Neurol. 2018;31:306–12.
pubmed: 29474316
pmcid: 5959203
doi: 10.1097/WCO.0000000000000546
Castillo-Gomez E, Oliveira B, Tapken D, Bertrand S, Klein-Schmidt C, Pan H, et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry. 2017;22:1776–84.
pubmed: 27502473
doi: 10.1038/mp.2016.125
Pan H, Steixner-Kumar AA, Seelbach A, Deutsch N, Ronnenberg A, Tapken D, et al. Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: a translational study from chronic life stress to brain injury. Mol Psychiatry. 2021;26:2471–82.
pubmed: 32089545
doi: 10.1038/s41380-020-0672-1
Wenke NK, Kreye J, Andrzejak E, van Casteren A, Leubner J, Murgueitio MS, et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol. 2019;85:771–6.
pubmed: 30843274
pmcid: 6593665
doi: 10.1002/ana.25460
Jaenisch N, Liebmann L, Guenther M, Hubner CA, Frahm C, Witte OW. Reduced tonic inhibition after stroke promotes motor performance and epileptic seizures. Sci Rep. 2016;6:26173.
pubmed: 27188341
pmcid: 4870642
doi: 10.1038/srep26173
Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96.
pubmed: 20842175
pmcid: 2948541
doi: 10.1038/nrn2911
Hara M, Martinez-Hernandez E, Arino H, Armangue T, Spatola M, Petit-Pedrol M, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology. 2018;90:e1386–e94.
pubmed: 29549218
pmcid: 5902781
doi: 10.1212/WNL.0000000000005329
Dalmau J. Letter by Dalmau Regarding Article, “Serum anti-NMDA (N-methyl-D-aspartate)-receptor antibodies and long-term clinical outcome after stroke (PROSCIS-B)”. Stroke. 2020;51:e28.
pubmed: 31928149
doi: 10.1161/STROKEAHA.119.027885
Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21:798–813.
pubmed: 33976421
pmcid: 8111372
doi: 10.1038/s41577-021-00543-w
Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology. 2004;62:912–9.
pubmed: 15037692
doi: 10.1212/01.WNL.0000115108.65264.4B
Lebrun F, Levard D, Lemarchand E, Yetim M, Furon J, Potzeha F, et al. Improving stroke outcomes in hyperglycemic mice by modulating tPA/NMDAR signaling to reduce inflammation and hemorrhages. Blood Adv. 2024;8:1330–44.
pubmed: 38190586
pmcid: 10943589
doi: 10.1182/bloodadvances.2023011744
Sperber PS, Gebert P, Broersen LHA, Kufner A, Huo S, Piper SK, et al. Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke. Brain Behav Immun Health. 2023;34:100705.
pubmed: 38033615
pmcid: 10684375
doi: 10.1016/j.bbih.2023.100705
Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A. Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke. Circ Res. 2022;130:1167–86.